- Researchers have developed a cerium-phytic acid (CePA) complex to treat metabolic dysfunction-associated steatohepatitis (MASH).
- CePA was found to inhibit lipid metabolism in hepatocytes by blocking mTOR signaling.
- In animal studies, CePA showed significant benefits in reducing liver fat accumulation and inflammation in MASH models fed a high-sugar, high-fat diet.
- CePA also demonstrated the ability to regulate lipid droplet accumulation and fibrosis in liver tissue, improving liver health.
- The study suggests that CePA may offer a new, effective treatment option for liver diseases, including MASH, by targeting the mTOR pathway.
Novel nanomedicine, mTOR repression, Allergy & Clinical Immunology, Oncology, Pharmacists